F-star Therapeutics, Inc.
FSTX · NASDAQ
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.27 | -0.03 | 0.00 | -0.04 |
| FCF Yield | -14.82% | -12.42% | -15.52% | 6.55% |
| EV / EBITDA | -5.01 | -5.17 | -1.66 | 10.69 |
| Quality | ||||
| ROIC | -19.32% | -18.82% | -10.92% | 4.24% |
| Gross Margin | 100.00% | 0.00% | 100.00% | 100.00% |
| Cash Conversion Ratio | 0.90 | 0.87 | 0.96 | 1.43 |
| Growth | ||||
| Revenue 3-Year CAGR | 24.05% | 122.12% | 148.53% | 2,766,118.21% |
| Free Cash Flow Growth | 1.09% | -44.36% | -271.29% | 163.29% |
| Safety | ||||
| Net Debt / EBITDA | 1.29 | 2.18 | 4.83 | -18.29 |
| Interest Coverage | -36.26 | -48.45 | -36.32 | -4.95 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 651.60 | 0.00 | 147.01 | 11.89 |